Antibody shields monkeys from HIV-like virus for months

April 27, 2016

Just one shot of a lab-produced antibody protected macaques against a sort of monkey HIV for nearly six months, said a study Wednesday into a potential vaccine alternative.

Exposed to simian HIV (SHIV) once a week, non-treated monkeys contracted the virus after just three weeks on average, the researchers said, whereas the trial monkeys remained virus-free for up to 23 weeks.

In human populations at high risk of contracting the AIDS-causing virus, such protection, even temporary, "could have a profound impact on virus transmission," the team of German and US-based researchers reported in the journal Nature.

They had examined "passive immunisation" as an alternative to an HIV vaccine, which experts fear may still be years off.

A vaccine works by priming the body to respond with germ-fighting antibodies whenever a virus or bacteria invades. It is long-lasting, sometimes for life.

"Passive immunisation" involves the transfer of antibodies generated by one person directly to another to provide protection, which is shorter-lived.

Antibody shots were used to protect travellers against Hepatitis A until a vaccine became available in the 1990s, and some hope the technique could stave off millions of HIV infections until a vaccine comes to the market.

Transferred antibodies had previously been shown to protect animals against HIV-like viruses for a day or two, but never as long as in this study.

Proof of concept

Since the outbreak started in the early 1980s, about 71 million people have been infected by HIV, and some 34 million have died, according to UN estimates.

There is no cure, and the only way of dealing with HIV is lifelong reliance on antiretroviral drugs, invented in the 1990s, to stop the virus from replicating.

The treatment carries side effects and is costly.

The quest for a vaccine has been long and frustrating, in spite of hundreds of millions of dollars in funding.

Some of the focus has shifted to antibodies, but this too proved complicated as each HIV antibody tends to target a specific virus strain.

In recent years, researchers have discovered that about 10-30 percent of HIV-infected people have a naturally-present, "broadly-neutralising" (bNAb) type of antibody which targets several strains at once.

Three of these were tested in the new study.

Each delayed infection in macaque monkeys, said the team—the first by up to 12 weeks, the second by 20 weeks, and the third by 23 weeks.

A single antibody shot "was protective against repeated low-dose SHIV infection for several months," the team wrote.

This served as "proof of concept" that periodic antibody shots may be useful as an alternative to vaccination, they said, though further research must confirm that the findings can be replicated in humans.

"When considered in the context of a potential exposure to HIV-1 in regions of the world where HIV-1 is endemic," wrote the team, such an infection barrier "could have a profound impact on virus transmission".

Explore further: Scientists boost potential of passive immunization against HIV

More information: Rajeev Gautam et al, A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges, Nature (2016). DOI: 10.1038/nature17677

Related Stories

Scientists boost potential of passive immunization against HIV

August 13, 2014
Scientists are pursuing injections or intravenous infusions of broadly neutralizing HIV antibodies (bNAbs) as a strategy for preventing HIV infection. This technique, called passive immunization, has been shown to protect ...

HIV antibody infusion safely suppresses virus in infected people

December 23, 2015
A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report in ...

NIH launches large clinical trials of antibody-based HIV prevention

April 7, 2016
Enrollment has begun in the first of two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection. Known as the AMP Studies, for antibody-mediated prevention, the trials ...

Researchers use antibody treatment to protect humanized mice from HIV

February 11, 2014
NIH-funded scientists have shown that boosting the production of certain broadly neutralizing antibodies can protect humanized mice from both intravenous and vaginal infection with HIV. Humanized mice have immune systems ...

Giving antibodies to infant macaques exposed to an HIV-like virus could clear infection

March 21, 2016
Scientists at the Oregon National Primate Research Center today revealed that infant rhesus macaques treated with antibodies within 24 hours of being exposed to SHIV, a chimeric simian virus that bears the HIV envelope protein, ...

Researchers unravel pathways of potent antibodies that fight HIV infection

March 3, 2016
One of the most crucial and elusive goals of an effective HIV vaccine is to stimulate antibodies that can attack the virus even as it relentlessly mutates.

Recommended for you

HIV vaccine protects non-human primates from infection

December 14, 2018
For more than 20 years, scientists at Scripps Research have chipped away at the challenges of designing an HIV vaccine. Now new research, published in Immunity, shows that their experimental vaccine strategy works in non-human ...

Roadmap reveals shortcut to recreate key HIV antibody for vaccines

December 11, 2018
HIV evades the body's immune defenses through a multitude of mutations, and antibodies produced by the host's immune system to fight HIV also follow convoluted evolutionary pathways that have been challenging to track.

Eliminating the latent reservoir of HIV

December 7, 2018
A new study suggests that a genetic switch that causes latent HIV inside cells to begin to replicate can be manipulated to completely eradicate the virus from the human body. Cells harboring latent HIV are "invisible" to ...

New research highlights why HIV-infected patients suffer higher rates of cancer

December 5, 2018
AIDS patients suffer higher rates of cancer because they have fewer T-cells in their bodies to fight disease. But new research examines why HIV-infected patients have higher rates of cancer—among the leading causes of death ...

Focus on resistance to HIV offers insight into how to fight the virus

November 30, 2018
Of the 40 million people around the world infected with HIV, less than one per cent have immune systems strong enough to suppress the virus for extended periods of time. These special immune systems are known as "elite controllers." ...

Patients with rare natural ability to suppress HIV shed light on potential functional cure

November 27, 2018
Researchers at Johns Hopkins have identified two patients with HIV whose immune cells behave differently than others with the virus and actually appear to help control viral load even years after infection. Moreover, both ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.